BRIEF-ZIOPHARM jumps in premarket after palifosfamide reached target number of progression-free survival events

NEW YORK Tue Feb 12, 2013 9:10am EST

NEW YORK Feb 12 (Reuters) - ZIOPHARM Oncology Inc : * Jumps 14.5 percent to $4.57 in premarket after palifosfamide reached target number of progression-free survival events

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.